首页> 美国卫生研究院文献>American Journal of Physiology - Endocrinology and Metabolism >Sustained activation of renal N-methyl-d-aspartate receptors decreases vitamin D synthesis: a possible role for glutamate on the onset of secondary HPT
【2h】

Sustained activation of renal N-methyl-d-aspartate receptors decreases vitamin D synthesis: a possible role for glutamate on the onset of secondary HPT

机译:肾脏N-甲基-d-天冬氨酸受体的持续激活会降低维生素D的合成:谷氨酸在继发HPT发作中的可能作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

N-methyl-d-aspartate (NMDA) receptors (NMDAR) are tetrameric amino acid receptors that act as membrane calcium channels. The presence of the receptor has been detected in the principal organs responsible for calcium homeostasis (kidney, bone, and parathyroid gland), pointing to a possible role in mineral metabolism. The aim of this study was to test the effect of NMDAR activation in the kidney and on 1,25(OH)2D3 synthesis. We determined the presence of NMDAR subunits in HK-2 (human kidney cells) cells and proved its functionality. NMDA treatment for 4 days induced a decrease in 1α-hydroxylase levels and 1,25(OH)2D3 synthesis through the activation of the MAPK/ERK pathway in HK-2 cells. In vivo administration of NMDA for 4 days also caused a decrease in blood 1,25(OH)2D3 levels in healthy animals and an increase in blood PTH levels. This increase in PTH induced a decrease in the urinary excretion of calcium and an increase in urinary excretion of phosphorous and sodium as well as in diuresis. Bone turnover markers also increased. Animals with 5/6 nephrectomy showed low levels of renal 1α-hydroxylase as well as high levels of renal glutamate compared with healthy animals. In conclusion, NMDAR activation in the kidney causes a decrease in 1,25(OH)2D3 synthesis, which induces an increase on PTH synthesis and release. In animals with chronic kidney disease, high renal levels of glutamate could be involved in the downregulation of 1α-hydroxylase expression.
机译:N-甲基-d-天冬氨酸(NMDA)受体(NMDAR)是四聚氨基酸受体,可充当膜钙通道。已经在负责钙稳态的主要器官(肾脏,骨骼和甲状旁腺)中检测到该受体的存在,这表明其可能在矿物质代谢中发挥作用。这项研究的目的是测试肾脏中NMDAR活化以及对1,25(OH)2D3合成的影响。我们确定了HK-2(人肾细胞)细胞中NMDAR亚基的存在并证明了其功能。 NMDA处理4天通过激活HK-2细胞中的MAPK / ERK途径,诱导了1α-羟化酶水平的降低和1,25(OH)2D3的合成。 NMDA的4天体内给药还导致健康动物的血液1,25(OH)2D3水平降低,血液PTH水平升高。 PTH的这种增加导致钙的尿排泄减少,磷和钠的尿排泄增加以及利尿。骨转换指标也增加。与健康动物相比,进行5/6肾切除术的动物显示低水平的肾脏1α-羟化酶以及高水平的肾脏谷氨酸。总之,肾脏中的NMDAR激活导致1,25(OH)2D3合成减少,从而导致PTH合成和释放增加。在患有慢性肾脏疾病的动物中,高水平的谷氨酸可能参与了1α-羟化酶表达的下调。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号